Telomerase activity is a wide tumor marker. Human telomerase reverse transcriptase (hTERT), the catalytic subunit of the telomerase, is transcriptionally upregulated exclusively in about 90% of cancer cells. In this study, we constructed a novel adeno-associated virus (AAV) vector containing the human interferon-β (hIFN-β) gene under the control of hTERT promoter (AAV-hTERT-hIFN-β) and investigated its antitumor effect against various human cancer cells in vitro. AAV-hTERT-hIFN-β displayed cancer-specific hIFN-β expression and cytotoxicity. The cytotoxic ratio was positively correlated with the time length of infection. AAV-hTERT-hIFN-β-mediated apoptotic morphology was observed by transmission electron microscopy. Flow cytometry assay also revealed that the cytotoxicity of AAV-hTERT-hIFN-β was mainly an apoptotic process. These data indicate that AAV in combination with hTERT-mediated therapeutic gene expression may open new possibilities for long-lasting and targeting gene therapy of varieties of cancers.
The development of safe and efficient gene transfer vehicles is critical for gene therapy on cancer [1] . A vast majority of these developments have been attempted by using adenoviral vectors and retroviral vectors. Adenoassociated virus (AAV)-based vectors are recently emerging nonpathogenic vectors with potential for cancer gene therapy. AAV belongs to the parvovirus family, a group of small single-stranded DNA viruses, with many advantageous features for human gene therapy. AAV was discovered as a co-infecting agent during an adenovirus outbreak, without any apparent pathogenicity [2] [3] [4] . Until now, no human disease caused by AAV has been detected. Moreover, AAV seems to be protective against bovine papillomavirus and adenovirus-mediated cellular transformation [5] [6] [7] . AAV does not induce cytotoxic effects and does not elicit a cellular immune response as commonly seen with other viral vectors [8] . Finally, AAV has the unique potential to integrate site specifically into the q-arm of human chromosome 19 [9, 10] , and the site-specific integration of an AAV provirus has no apparent effect on cell growth, morphology, or differentiation, and leads to a long-lasting therapeutic gene expression. Long-term undiminished expression over 11.2 years of the AAV transduced genes has been reported after i.m. delivery [11] .
Owing to the broad infection range of AAV, no targeting therapeutic gene expression can be achieved unless a specific promoter/enhancer system is used. Therefore, the use of a regulatory element for tumor cell-restricted gene expression with limited toxicity for benign tissues is necessary. Many tissue or tumor specific transcriptional regulatory sequences have been developed to restrict therapeutic gene expression in tumor cells [1] , such as flt-1 promoter directing the expression in all vescular beds except for the liver, CEA (Carcinama Embryonic Antigen) promoter preferentially targeting to colonectal and lung cancer, AFP promoter in hepatocellular carcinoma cells. However, their applications are restricted to only a narrow range of tumors as these promoters are only active in certain type of cancer from which they are derived. To overcome this problem, promoters that can operate in a variety of tumors are desired.
Recently, telomerase has been recognized as a new wide-range tumor marker [12, 13] . It has been reported that telomerase activity is significantly higher in about 90% of cancers and correlates well with the degree of malignancy [14, 15] . Human telomerase has three subunits: the RNA component (hTER), the telomerase-associated protein (hTEP1), and the telomerase reverse transcriptase protein subunit (hTERT) [16] [17] [18] . The catalytic subunit of telomerase, hTERT, is the determinant of the telomerase activity. Moreover, the expression of hTERT gene is transcriptionally upregulated in a variety of cancer cells while repressed in normal cells [19, 20] . Therefore, its promoter region has been cloned and used in targeting cancer gene therapy to restrict the expression of exogenous genes to various cancer cells [21] [22] [23] [24] [25] , which is also what we are doing [26] . We speculated that hTERT promoter could be an excellent candidate for generating cancerspecific AAV vector system [26] .
In this study, we described a novel AAV vector containing human interferon-β (hIFN-β) under the control of the hTERT promoter, and demonstrated that AAV-hTERThIFN-β specifically killed a panel of tumor cells, but not normal cells. Because of the long-lasting gene expression by AAV delivery and tumor-targeting gene expression mediated by hTERT promoter, AAV-hTERT-transgene offers a promising therapeutic platform for a variety of cancers with the hallmark of high telomerase activity.
Materials and Methods

Plasmids
The AAV helper-free system (based on AAV-2) containing four plasmids, pAAV-MCS (ITR containing vector), pAAV-GFP (another ITR containing vector), pAAV-RC (carrying AAV-2 replication and capsid genes) and phelper (carrying adenovirus-derived genes) was a gift from Dr. Hui-Zhen SHENG (Institute of Biochemistry and Cell Biology, SIBS, CAS). pAd/hTERT (a gift from Dr. Bingliang FANG, University of Texas MD Anderson Cancer Center, Houston, TX, USA) was digested with MluI/SnaBI and hTERT fragment (-378 bp/+78 bp) was ligated into the MluI/SnaBI sites of pAAV-GFP to construct the control plasmid pAAV-hTERT-GFP. To construct pAAV-hTERT-hIFN-β, hTERT promoter was cloned into the upstream of hIFN-β in the pCA13-hIFN-β plasmid (kept in our lab). Then hTERT-hIFN-β was amplified by PCR with the following primers: 5'-gctcccagtggattcgcg-3' (sense) and 5'-ctagctggatcctcagtttcggaggtaacctg-3' (antisense, BamHI site underlined). The PCR product was digested with BamHI and ligated into the SnaBI/BamHI sites of pAAV-MCS, and produced pAAV-hTERT-hIFN-β.
Cells and culture
The HEK293 cell line (human embryonic kidney containing the E1 region of Ad5), human fibrosarcoma cell line HT1080, human lung fibroblasts HFL-1, human hepatocarcinoma cells HepG2 and human colorectal cancer cell line SW620 were all purchased from ATCC. Human breast cancer cell line Bcap37, was purchased from Shanghai Cell Collection, Chinese Academy of Sciences [27] . HEK293, HT1080, SW620, and HepG2 cells were cultured in DMEM (Gibco BRL) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco BRL), 4 mM glutamine, 50 U/ml penicillin and 50 µg/ml streptomycin. Bcap37 and HLF-1 cells were grown in RPMI 1640 supplemented with 10% FBS.
rAAV production
Recombinant AAV (rAAV) package was performed using the AAV helper-free system according to the manufacture's instruction. Briefly, HEK293 cells were cultured at 3×10 6 cells per 10-cm tissue culture plate and cotransfected with pAAV-hTERT-GFP or pAAVhTERT-hIFN-β, pAAV-RC and phelper (1:1:1, with 10 µg respectively) using calcium phosphate-based method 24 h later. 6 h after transfection, culture medium was changed into complete growth medium. 66-72 h later, cells and supernatant were collected as rAAV primary stocks.
Purified viral stocks were obtained by chloroform extraction as previously described [29] . The resulting rAAVs were named as AAV-hTERT-GFP and AAV-hTERThIFN-β. They were titered according to the protocol of AAV helper-free System. Briefly, AAV-hTERT-GFP was diluted over a 10-fold series from 10 -5 to 10 -10
. Each dilution was separately added to HT1080 cells seeded on 12-well plates. After 48 h of incubation at 37 °C, titer was determined using fluorescence microscopy by calculating the fraction of fluorescent cells in microscopic fields. The titer of AAV-hTERT-hIFN-β was calculated by reading absorbance at 260 nm and comparing with the corresponding titer of AAV-hTERT-GFP.
RT-PCR for detection of hIFN-β β β β β transcription
After AAV-hTERT-hIFN-β infection for indicated time, total cellular RNA was isolated using Trizol reagent (Life Technologies) according to the manufacturer's protocol. RT-PCR was performed with total RNA (2 µg) using the First strand RT-PCR kit (Stratagene). A cDNA equivalent of 1 ng RNA was amplified by PCR using primers specific to the target genes. The primer sets used were as follows: hIFN-β, 5'-atgaccaacaagtgtctcca-3' (sense) and 5'-tcagtttcggaggtaacctg-3' (antisense); β-actin, 5'-ccagccatgtacgttgctatccag-3' (sense) and 5'-ggaaccgctcattgccaatggtga-3' (antisense). The thermal cycles were: 94 °C for 1 min, 53 °C for 1 min, 72 °C for 1 min. The amplified products were fractionated on a 1.5% agarose gel containing 0.5 mg/ml ethidium bromide and DNA patterns were visualized under UV light.
ELISA for detection of hIFN-β β β β β expression
After AAV-hTERT-hIFN-β infection for indicated time, hIFN-β in the supernatant was analyzed by hIFN-β ELISA kit (PBL Biomedical Laboratories) according to the manufacture's instruction. Diluted standards and supernatants containing hIFN-β were added at 100 µl/well in 96-well plates that were coated with mouse antihIFN-β monoclonal antibody. After incubation for 1 h at 24 °C and washing for three times, 50 µl 0.4 µg/ml biotinylated mouse anti-hIFN-β antibody at was added per well, and incubated for 1 h at 24 °C with continual shaking. After washing, 100 µl streptavidin-HRP working solution was added per well and incubated for 1 h at 24 °C. After washing, 100 µl freshly prepared chromogen tetramethyl benzidine (TMB) was added per well and incubated for 15 min at 24 °C with continual shaking in the dark, followed by addition of 50 µl stop solution per well. The optical density of the plates was measured at 450 nm (reference filter 650 nm).
Cell viability assay
HLF-1, SW620, HepG2 or Bcap37 cells were seeded at a density of 1×10 4 cells/well in a flat-bottomed 96-well plate. After AAV-hTERT-GFP or AAV-hTERT-hIFN-β infection for 1-5 d, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was performed to measure the viability of cells everyday. Briefly, 20 µl 5 mg/ml MTT in PBS was added to each well. After 4 h at 37 °C, MTT was slightly removed and 100 µl of lysis buffer (10% SDS, 50% dimethyl formamide) was added. The plates were incubated for 7 h at 37 °C before analysis on an ELISA reader (Bio-Rad) at 595 nm.
Electron microscopy
Cells were fixed with 2.5% glutaraldehyde in PBS, pH 7.4, post-fixed in 1% osmium tetroxide, followed by staining with 2% uranyl acetate. Samples were dehydrated serially through increasing the concentration of ethanol and embedded in Epon 812. Sections were examined with a Hitachi H-600 transmission electron microscope.
Flow cytometry
Cells were harvested at 1×10 6 cell/ml, washed with PBS, and fixed in citric acid buffer for 30 min at room temperature. After centrifugation, cells were digested with 100 µl 0.5 g/L RNase A at 37 °C for 30 min, then 400 µl propidium iodide solution (100 µg/ml propidium iodide, 1% Triton X-100, 150 mM NaCl) was added. 30 min later, the apoptosis ratio was analyzed using a FACScan flow cytometer equipped with CellQuest smf ModFIT LT for mac V1.01 software (Becton Dickinson).
Statistical analysis
Data were expressed as mean ± SD. Student's t-test was applied to study the relationship between the different variables. Statistical significance was taken at P<0.05.
Results
Purification and titration of rAAVs
The capsid of AAV-2 is composed of three proteins, VP1 (87 kD), VP2 (72 kD) and VP3 (62 kD), which form the 60 subunits of the AAV-2 viral capsid at a 1:1:20 ratio [29] . To verify the obtained rAAVs in this study, 5 µl rAAVs were separated by 10% SDS-PAGE. The result shows that both the purified AAV-hTERT-GFP and AAV-hTERT-hIFN-β (Fig. 1 ) exhibit these three characterized proteins on the stained gel as shown in Fig. 2 , and their contents are consistent with the 1:1:20 ratio after density scanning by computer. In addition, the background of the gel is clean, which indicates that rAAVs has a high purity without contamination by other proteins. The purity of these two rAAVs was demonstrated to be higher than 95%.
The titers of these two rAAVs were determined as described in "Materials and Methods". By calculating the fraction of fluorescent HT1080 cells under fluorescence microscopy after infection for 48 h, the transfection titer of AAV-hTERT-GFP was detected as 8×10 11 TU/ml. Accordingly, the titer of AAV-hTERT-hIFN-β was detected as 2×10 11 TU/ml by optical density reading and comparison with the titer of AAV-hTERT-GFP. sion was detected in the cell culture medium. The results showed that AAV-hTERT-GFP could lead to tumor cells specific GFP expression (Fig. 4) , while nearly no cells with green fluorescence were observed in HFL-1 cells. ELISA assay also showed that AAV-hTERT-hIFN-β could restrict hIFN-β expression in tumor cells but not in HFL-1 cells (Table 1 ). These results demonstrate that our rAAV system is evidently tumor targeting.
Characterization of rAAVs
To identify the control virus AAV-hTERT-GFP and the therapeutic virus AAV-hTERT-hIFN-β, HT1080 cells were infected by both virus at a multiplicity of infection (MOI) of 400 TU/cell. RT-PCR was performed two days later to detect the hIFN-β expression. As shown in Fig. 3 , AAV-hTERT-hIFN-β could produce marked hIFN-β in HT1080 cells, while AAV-hTERT-GFP did not. We further verified hIFN-β expression using ELISA assay. In accordance with the result of RT-PCR, ELISA assay showed the concentration of hIFN-β in the cell culture medium reached (3287.4 ± 316.5) pg/ml two days after AAV-hTERT-hIFN-β infection, while no obvious hIFN-β expression was detected in the medium in the AAV-hTERT-GFP infection group.
Tumor specific gene expression mediated by rAAVs
To investigate whether rAAVs could mediate tumor specific gene expression, the normal cell line HFL-1 and three tumor cell lines SW620, HepG2 and Bcap37 were infected with AAV-hTERT-GFP or AAV-hTERT-hIFN-β at a MOI of 400 TU/cell. Two days later, the cells were detected under fluorescence microscopy or hIFN-β expres- 28.9 ± 6.5 5872.1 ± 487.2* 4987.5 ± 297.8* 2976.5 ± 201.6* The results were represented as means ± SD from three independent experiments. *P<0.0001 compared with the hIFN-β expression level of other cell lines. Table 1 Tumor targeting hIFN-β β β β β expression by AAV-hTERThIFN-β β β β β
Fig. 2 SDS-PAGE of AAV-hTERT-GFP and AAV-hTERThIFN-β β β β β
In vitro tumor specific cytotoxicity of AAV-hTERThIFN-β β β β β
To study whether rAAVs could mediate tumor specific cytotoxicity, both the normal (HFL-1) and tumor (SW620, HepG2 and Bcap37) cell lines were infected with AAV-hTERT-GFP or AAV-hTERT-hIFN-β at a MOI of 400 TU/cell. Cell viability was measured by MTT assay from day 1 to day 5. As shown in Fig. 5 , AAVhTERT-hIFN-β could specifically kill tumor cells (P<0.01
Fig. 5
In vitro tumor specific cytotoxicity of AAV-hTERT-hIFN-β β β β β
The normal cell line HFL-1 and three tumor cell lines SW620, HepG2 and Bcap37 were treated as above. Cell viability was measured by MTT assay from 1 day to 5 day. Data were represented as mean ± SD (n=4). The experiment was repeated once with essentially the same results.
Fig. 4 Tumor specific GFP expression by AAV-hTERT-GFP
The normal cell line HFL-1 (A) and three tumor cell lines SW620 (B), HepG2 (C) and Bcap37 (D) were infected with AAV-hTERT-GFP at a MOI of 400 TU/cell. Two days later, the green fluorescent cells were observed under fluorescence microscopy.
Fig. 7 Flow cytometry
The normal cell line HFL-1 and three tumor cell lines SW620, HepG2 and Bcap37 were infected with AAV-hTERT-hIFN-β at a MOI of 400 TU/cell. Three days later, FACS assay was performed to detect the apoptotic ratio.
compared with AAV-hTERT-GFP group for tumor cell lines; P>0.05 compared with AAV-hTERT-GFP group for HFL-1 cells), and the cytotoxicity was time-dependent. Among the three tumor cells lines, SW620 was most sensitive, with only 18% survival cells at the 5th day. The control virus AAV-hTERT-GFP had no effect on both normal cells and tumor cells, which suggested it was hIFN-β expression that led to the cytotoxic effect and AAV vector itself had no effect on cell viability. These results demonstrated that our rAAV system could lead to an obvious tumor specific cytotoxic effect by transgene expression in vitro, and was potential for targeting tumor therapy in vivo.
Apoptosis induced by AAV-hTERT-hIFN-β
To investigate whether AAV-hTERT-hIFN-β killed tumor cells through apoptosis or necrosis, SW620 cells were infected with AAV-hTERT-GFP or AAV-hTERThIFN-β at a MOI of 400 TU/cell. Five days later, electron microscopy observation revealed chromatin condensed in lumps at the inner side of the nuclear envelope and dilation of the endoplasmic reticulum to large vesicles with or without membranes material in the lumen in cells infected by AAV-hTERT-hIFN-β [ Fig. 6(B) ], while not so in AAV-hTERT-GFP infected ones [ Fig. 6(A) ]. Accordingly, AAV-hTERT-hIFN-β specifically killed tumor cells through promoting apoptotic process. It was believed that hIFN-β could act as a stimulator of apoptosis, so the apoptotic morphology observed might be mediated by hIFN-β.
FACS assay confirmed this result more precisely. HFL-1 and three tumor cell lines SW620, HepG2 and Bcap37 were infected with AAV-hTERT-hIFN-β at a MOI of 400 TU/cell. Three days later, FACS assay revealed that AAV-hTERT-hIFN-β could induce apoptosis in SW620, HepG2 and Bcap37 cells, with the apoptotic ratio of 51.91%, 40.21%, and 35.73% respectively (Fig. 7) , but no obvious apoptosis was detected in HFL-1 cells. The apoptotic ratio of each kind of tumor cells was consistent with the cytotoxic ratio shown in Fig. 5 , which suggested that AAV-hTERT-hIFN-β killed tumor cells by promoting the apoptotic process. Moreover, the apoptotic ratio was correlated with the hIFN-β expression level in each kind of cells (Table 1) , which further demonstrated the apoptosis was the direct effect of hIFN-β secreted after AAV-hTERThIFN-β infection.
Discussion
rAAV is an ideal vector for cancer gene therapy because of the absence of immunogenicity and long-term expression capabilities. Till now, no human disease caused by AAV has been detected. Moreover, undiminished longterm persistent expression of rAAV-encoded proteins has been reported in a variety of studies [30, 31] . The major limitation of rAAV is that it can infect a variety of human and animal cell types of different origin. The in vivo efficacy of rAAV was proven in murine and nonhuman primate models using a variety of candidate genes and target tissues [32] . Use of tissue-specific promoters represents one strategy to achieve restricted expression of the transgene in target cells. Furthermore, because native promoters and other regulatory elements are not foreign to the target cells or the immune system, promoter inactivation may be reduced over time, allowing longer expression of the transgene. Recent preclinical studies also indicate the feasibility of regulated expression of AAV-transgenes in vivo in murine and nonhuman primate models [33] .
In the present study, we described a novel tumortargeting AAV vector, in which hTERT promoter was used to restrict therapeutic gene expression in tumor cells. hTERT promoter was broadly used to construct therapeutic vectors targeting to telomerase-positive tumor cells [34] [35] [36] , and restrict therapeutic gene expression in such tumor cells [37] [38] [39] [40] . Given that the telomerase activity is elevated in the vast majority of human tumors, AAV-hTERT-transgene vector system could be a powerful anticancer agent to a wide range of human malignancies from different etiology.
We used hIFN-β as a therapeutic gene to explore the tumor specificity of AAV-hTERT-transgene. Tumor specific cytotoxicity was observed after AAV-hTERThIFN-β infection into cells. Apoptosis assay revealed cancer cell death was due to hIFN-β-mediated apoptosis. These results suggested that AAV-hTERT-transgene system could specifically express transgene in tumor cells and transgene could exert its native oncolytic function on tumor cells. The control vector AAV-hTERT-GFP had no such effect on both normal and tumor cells, which showed the AAV-hTERT-transgene vector itself was not toxic to cells.
One major concern about the hTERT promoter-driven transgene is their potential toxicity to some normal cells, in which the telomerase is also active, including some progenitor cells of hematopoietic, epithelial, and gut origin, as well as hair follicles undergoing mitosis [18, [41] [42] [43] . There is putative toxicity when AAV-hTERT-transgene is delivered systemically. It has been reported that expression of rAAV transgene is higher in cells that are actively dividing [44, 45] , which supports that AAV-hTERTtransgene could only induce little transgene expression in these inactive cells. Another support for the less toxicity in vivo is that telomerase activity in those cells is only transient [46] , suggesting that toxic effects arising from AAV-hTERT-transgene, if any, may be transient. Nevertheless, it is important to investigate the longterm toxic effects of AAV-hTERT-transgene in systemic delivery. However, other strategies could be used to reduce the potential toxicity of AAV-hTERT-transgene, such as genetic and immunological modifications of vector tropism.
Further studies on the AAV-hTERT-transgene system are in progress now. One aspect involves delivery of two different therapeutic genes by this system. Although there is a size limit in the packaging of foreign genes in rAAV, most of the therapeutic genes in the context of cancer therapy are well within the packaging limits of rAAV, either alone or in tandem. Provision of two different therapeutic genes from the same vector may yield added therapeutic benefits because different therapeutic factors may work through different mechanism. We are now working on the combination of hIFN-β and TRAIL, based on the report that hIFN-β and TRAIL combination treatment had more potent apoptotic and anti-growth effects when compared with either cytokine alone in melanoma cells lines [47] .
In conclusion, we have proved that AAV-hTERTtransgene could restrict the transgene expression to the telomerase-active tumor cells and lead to cancer specific cytotoxic effect mediated by transgene. hTERT promoter is active in cancers from very different etiology, indicating that AAV-hTERT-transgene could be used in a wide range of human malignancies. Our preliminary research on constructing a highly specific and wide-ranged rAAV system pave the way for future studies. 
